Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s Pharmaceutical TechnologyThe real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's VyalevNeuroscienceRead full story pharminent July 1, 2026 (Last updated: July 1, 2026) Pharmaceutical Technology The real-world data study tracked Parkinson’s disease patients for 12 months during treatment with AbbVie’s Vyalev Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory failNext: Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program Related Stories Clinical Data GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail pharminent July 17, 2026 Clinical Data AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug pharminent July 15, 2026 Clinical Data AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance pharminent July 15, 2026
